Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- 61% of Clinics that Issue Legal Prescriptions Claim Premium for Generic-Name Prescribing: JMA Survey
August 3, 2012
- JMA to Draft COI GLs by End of Year
August 3, 2012
- JMA Executive Board Member Komori Calls For Efforts for “Joint Fight” by Municipalities to Slash IPV Price
July 30, 2012
- 4 Pharmaceutical Associations Issue Joint Statement Calling For Eradicating Online Illegal Drug Sales
July 27, 2012
- EFPIA Submits Opinion Letter to MHLW Calling for Review of Priority Focus on Japanese Companies for Blood Plasma Products
July 27, 2012
- Hiroshima Wholesale FTC Sees “Gradual Effects” in Correcting Labor Services in Cooperation with Pharmacists
July 25, 2012
- 4.5 Bil. Yen Tax Hike Estimated in FY2012 Tax Reform: JPMA
July 17, 2012
- Wholesaler FTC to Make Serious Efforts for Improving “Services of Convenience”
July 13, 2012
- Japan Should Not Copy Foreign HTA Systems: Mr Grainger of PhRMA
July 12, 2012
- JMA Asks Sanofi Pasteur to Lower Price for Inactivated Polio Vaccine
July 9, 2012
- 60% of Respondents Are Unaware That Colorectal Cancer is Asymptomatic Ill: Survey
July 9, 2012
- OPIR Says Surplus of Drug Imports “Unrelated to International Competitiveness of Domestic Industry”
July 6, 2012
- JPMA Calls for Restoration of 30% Maximum Deduction Rate in R&D Tax Credit System
July 4, 2012
- 30% of Medical Institutions Introduce Generic Name Prescribing: Yakukeiren Survey
July 3, 2012
- JGA Begins Posting Information on Out-of-Stock Products, Delayed Shipments on Website
July 3, 2012
- JPA Vice President Miura Calls for Discussions on Role of Pharmacies; Raises Question about Dividends Paid by Listed Pharmacies
June 27, 2012
- Legal Prescription Receipt Rate at Record-High 64.6% in FY2011: JPA
June 26, 2012
- JPWA, NPhA Confirm Need for Thorough Efforts “at Ground Level” for Distribution Improvements
June 25, 2012
- Products from 2nd Round of Development Requests Now Eligible for PDSC Subsidies
June 19, 2012
- Astellas’ Nogimori New Acting President of IFPMA
June 18, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…